Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
NCT ID NCT05926362
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receiving treatment. The goal is to see how well the finger-prick results match lab results, which could pave the way for simpler, more convenient blood monitoring.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If the finger-prick device proves accurate, it could enable convenient at-home blood monitoring for cancer patients and others.
- What could go wrong
- This is an early-stage device validation study. The finger-prick results may not match lab standards closely enough for clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients who are currently receiving standard of care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy and have received at least one cycle AND healthy volunteers.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
CANCER COHORT: Subjects fulfilling all of the following inclusion criteria are eligible for the study: * Age ≥18 years old at the time of study entry * Currently receiving standard-of-care systemic anti-cancer therapy (chemotherapy, immunotherapy, endocrine and targeted therapy) for solid organ malignancy * Scheduled to be undergoing routine venous laboratory blood tests as part of the standard of care * Able to provide capillary whole blood donation from pricking three different fingers on one hand * Can provide written informed consent * In the Investigator's opinion, is able and willing to comply with all study requirements The presence of any one of the following exclusion criteria will lead to the exclusion of the subject: * History or current diagnosis of haematological malignancy (including bone and lymph) * Inadequate use and understanding of the English language, requiring a translator HEALTHY COHORT Subjects fulfilling all of the following inclusion criteria are eligible for the study: * Age ≥18 years old at the time of study entry * Can provide written informed consent * Have an NHS number (to enable ordering and tracking of laboratory FBC tests) * Registered with a GP * In the Investigator's opinion, is able and willing to comply with all study requirements The presence of any one of the following exclusion criteria will lead to the exclusion of the subject: * Inadequate use and understanding of the English language, requiring a translator * Been hospitalised within 90 days prior to their study visit * Donated whole blood or plasma to a blood bank within the 90 days prior to the study visit * History of vasovagal syncope following blood draw * History or current diagnosis of the following conditions: * Cancer * Cardiovascular disease * Chronic kidney disease or end-stage renal disease * Bleeding disorder (including but not limited to Immune Thrombocytopenia (ITP), hemophilia, von Willebrand disease (VWD)) * Blood clotting disorder (including but not limited to thrombophilia, antiphospholipid syndrome) * G6PD deficiency * Inflammatory bowel disease * Myelodysplastic syndrome * Ebola * Tuberculosis * HIV * Hepatitis B or C * Current diagnosis of Epstein-Barr Virus or Cytomegalovirus * Current diagnosis of diabetes mellitus, unless controlled by diet alone OR participant has been taking the same dose of the same medication for 4 weeks or more and are feeling fit and well. * Undergone organ transplantation * Anemia, unless the participant is feeling fit and well (no dizziness, fatigue, shortness of breath etc)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy subjects are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust
Aylesbury, Buckinghamshire, HP21 8AL, United Kingdom
-
Wycombe Hospital, Buckinghamshire Healthcare NHS Trust
High Wycombe, Buckinghamshire, HP11 2TT, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple reaching exercise strengthen ankles and cut injury risk?
- Urine chemistry may hold key to safer dosing for brain drug
- Could a skin patch replace IV sedation? early test in healthy adults
- Can a common amino acid help your body build more protein?
- Can a radioactive antibody seek out and destroy Hard-to-Treat tumors?
- Fine-Mist inhalers aim to reach deep lungs in COPD